
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma Inc. is positioned favorably due to its innovative investigational drug assets targeting Alzheimer's disease, which have shown potential efficacy in suppressing key hallmarks of the condition. The company's current valuation presents an attractive opportunity, as evidenced by an increased Net Present Value (NPV) analysis projecting significant upside from the prevailing share price. Furthermore, the anticipation of additional positive data from ongoing studies serves as a potential catalyst for further stock performance enhancement.
Bears say
IGC Pharma Inc reported a net loss of $1.6 million, with earnings per share (EPS) of $(0.02), aligning with consensus estimates but indicating a lack of profitability. The company's focus on developing investigational drugs for Alzheimer's disease presents substantial risks, including potential failures in demonstrating safety and efficacy, along with obtaining necessary regulatory approvals. Additionally, the company faces liquidity and balance sheet risks, heightened competition, and shifting investor sentiment towards biotech stocks, all contributing to a negative outlook on its financial stability and growth potential.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares